×
About 10,965 results

U.S. Energy Dept. OKs 5th exchange of 400,000 barrels of crude from SPR
https://www.reuters.com/article/usa-oil-spr/u-s-energy-dept-oks5th-exchange-of-400000-barrels-of-crude-from-spr-idUSW1N2SK00Q

Jan 18th, 2022 - WASHINGTON, Jan 18 (Reuters) - The U.S. Department of Energy said on Tuesday it had approved a fifth exchange of 400,000 barrels of crude oil for release to Atlantic Trading and Marketing Inc. from the Strategic Petroleum Reserve. Companies that receive SPR crude oil through the exchange agree to return the amount of crude oil received, as well as an additional amount, dependent upon the length...

U.S. identifies bird flu strain found in South Carolina duck
https://www.reuters.com/article/usa-avianflu/u-s-identifies-bird-flu-strain-found-in-south-carolina-duck-idUSL1N2TY1Y4

Jan 18th, 2022 - CHICAGO, Jan 18 (Reuters) - The U.S. Department of Agriculture on Tuesday identified the strain of highly pathogenic avian flu found in a wild duck in South Carolina as H5N1. That strain has caused a wave of outbreaks of bird flu in poultry in Europe and Asia. H5N1 is one of the few bird flu strains that has passed to humans, although U.S. officials have said there is a low risk to people from ...

Gilead says counterfeiting network sold $250 mln worth of its HIV drugs
https://www.reuters.com/article/gilead-sciences-hiv/gilead-says-counterfeiting-network-sold-250-mln-worth-of-its-hiv-drugs-idUSL4N2TY3VJ

Jan 18th, 2022 - Jan 18 (Reuters) - Gilead Sciences Inc said on Tuesday that tampered and counterfeit versions of its HIV treatments worth $250 million were sold to pharmacies over two years by a network of drug distributors and suppliers. The drugmaker said in August that distributors not authorized by Gilead to sell its HIV treatments, Biktarvy and Descovy, have sold counterfeits to pharmacies where genuine G...

EU regulator says mRNA COVID-19 shots do not complicate pregnancies
https://www.reuters.com/article/health-coronavirus-vaccines-pregnancy/eu-regulator-says-mrna-covid-19-shots-do-not-complicate-pregnancies-idUSL4N2TY3EZ

Jan 18th, 2022 - Jan 18 (Reuters) - A review by the European Union’s drug regulator found that mRNA COVID-19 vaccines do not cause pregnancy complications for expectant mothers and their babies, after it assessed data from studies involving around 65,000 pregnancies at different stages. The European Medicines Agency said on Tuesday the review conducted by its COVID-19 task force also found that COVID-19 shots a...

Merck signs supply deal with UNICEF for 3 mln courses of COVID-19 drug
https://www.reuters.com/article/health-coronavirus-merck-co-treatment/merck-signs-supply-deal-with-unicef-for-3-mln-courses-of-covid-19-drug-idUSL4N2TY2UI

Jan 18th, 2022 - Jan 18 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Tuesday they had signed a supply agreement with the United Nations Children’s Fund (UNICEF) for 3 million courses of their COVID-19 drug. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

Kremlin says no point discussing media speculation on SWIFT sanctions
https://www.reuters.com/article/ukraine-crisis-russia-swift-kremlin/kremlin-says-no-point-discussing-media-speculation-on-swift-sanctions-idUSR4N2T602I

Jan 18th, 2022 - MOSCOW, Jan 18 (Reuters) - The Kremlin said on Tuesday there was no point in discussing media speculation that Western governments were no longer considering cutting Russia off from the SWIFT global payments system, preferring to focus instead on their official actions. A source-based report on Monday by German business newspaper Handelsblatt, which said economic sanctions targeting major Russi...

Canada study of Merck's COVID-19 oral treatment is moving more slowly - health minister
https://www.reuters.com/article/health-coronavirus-canada-merck-co/canada-study-of-mercks-covid-19-oral-treatment-is-moving-more-slowly-health-minister-idUSL1N2TX1H2

Jan 17th, 2022 - OTTAWA, Jan 17 (Reuters) - Canada’s study into whether to approve Merck & Co Inc’s COVID-19 oral antiviral treatment “is moving more slowly”, federal Health Minister Jean-Yves Duclos said on Monday. “There are some specific issues for this medication,” Duclos told reporters after Ottawa approved an oral antiviral treatment by Pfizer Inc, but did not give details. In its pivotal clinical trial, ...

BRIEF-Canada Receives 30,400 Courses Of Pfizer's COVID-19 Oral Antiviral Treatment; 120,000 More Expected By End-March - Statement
https://www.reuters.com/article/brief-canada-receives-30400-courses-of-p/brief-canada-receives-30400-courses-of-pfizers-covid-19-oral-antiviral-treatment-120000-more-expected-by-end-march-statement-idUSS0N2S3024

Jan 17th, 2022 - Jan 17 (Reuters) - * CANADA HAS RECEIVED SHIPMENT OF 30,400 TREATMENT COURSES OF PFIZER’S COVID-19 ORAL ANTIVIRAL TREATMENT; 120,000 MORE EXPECTED BY END OF MARCH - STATEMENT Source text : bit.ly/3FGHF2F

BRIEF-Canada has approved Pfizer's COVID-19 oral antiviral treatment - government website
https://www.reuters.com/article/brief-canada-has-approved-pfizers-covid/brief-canada-has-approved-pfizers-covid-19-oral-antiviral-treatment-government-website-idUSL1N2TX15X

Jan 17th, 2022 - Jan 17 (Reuters) - Pfizer Inc: * CANADA HAS APPROVED PFIZER’S COVID-19 ORAL ANTIVIRAL TREATMENT - GOVERNMENT WEBSITE Source text for Eikon: Further company coverage: (Reporting by David Ljunggren)

BRIEF-GSK And Pfizer Hold Out For 60 Bln Stg Bid For Consumer Health Unit - FT
https://www.reuters.com/article/brief-gsk-and-pfizer-hold-out-for-60-bln/brief-gsk-and-pfizer-hold-out-for-60-bln-stg-bid-for-consumer-health-unit-ft-idUSFWN2TV037

Jan 16th, 2022 - Jan 16 (Reuters) - GlaxoSmithKline PLC: * GSK AND PFIZER HOLD OUT FOR £60BN BID FOR CONSUMER HEALTH UNIT - FT * INVESTORS PUSH FOR HIGHER PRICE OR SPIN-OFF AFTER REJECTING UNILEVER’S £50 BILLION OFFER- FT Source text for Eikon: Further company coverage:

GSK says it rejected 50 bln-pound Unilever bid for consumer assets
https://www.reuters.com/article/gsk-unilever-bid-rejection/gsk-says-it-rejected-50-bln-pound-unilever-bid-for-consumer-assets-idUSL9N2SZ00A

Jan 15th, 2022 - LONDON, Jan 15 (Reuters) - Pharmaceutical group GlaxoSmithKline said it had rejected a 50-billion-pound ($68.4 billion) bid by Unilever for its consumer healthcare assets which GSK said “fundamentally undervalued” the business and its future prospects. GSK said in a statement on Saturday that it had received three bids from Unilever, the latest on Dec. 20 comprising 41.7 billion pounds in cash ...

BRIEF-Arcellx Inc Files For IPO Of Up To $100 Million – SEC Filing
https://www.reuters.com/article/brief-arcellx-inc-files-for-ipo-of-up-to/brief-arcellx-inc-files-for-ipo-of-up-to-100-million-sec-filing-idUSFWN2TU13Z

Jan 14th, 2022 - Jan 14 (Reuters) - GlaxoSmithKline PLC: * ARCELLX INC FILES FOR IPO OF UP TO $100 MILLION – SEC FILING * ARCELLX INC - EXPECT SHARES WILL TRADE ON NASDAQ GLOBAL MARKET UNDER THE SYMBOL “ACLX” * ARCELLX INC SAYS BOFA SECURITIES, SVB LEERINK , BARCLAYS, WILLIAM BLAIR ARE UNDERWRITERS TO IPO * ARCELLX INC SAYS TAKEDA VENTURES, INC BENEFICIALLY OWNED 5.43% OF COMMON SHARES OF CO PRIOR TO IPO * ARCE...

FACTBOX-U.S. holiday sales over the past decade
https://www.reuters.com/article/retail-holidayshopping/factbox-u-s-holiday-sales-over-the-past-decade-idUSL4N2TS351

Jan 14th, 2022

REFILE-Hormones help trans teens, U.S. study finds, as state bans loom
https://www.reuters.com/article/usa-lgbt-health/refile-hormones-help-trans-teens-u-s-study-finds-as-state-bans-loom-idUSL8N2TU2P2

Jan 14th, 2022 - (Fixes typo in 4th paragraph) LONDON, Jan 14 (Thomson Reuters Foundation) - Transgender teenagers prescribed cross-sex hormones are less likely to have suicidal thoughts and other mental health problems as adults, research showed this week as lawmakers in several U.S. states seek to ban the treatment among minors. Debate has grown about the age at which transition treatment should begin as more...

PRESS DIGEST-Financial Times - Jan 14
https://www.reuters.com/article/britain-press-ft/press-digest-financial-times-jan-14-idUSL4N2TU046

Jan 14th, 2022 - Jan 14 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Prince Andrew to lose royal titles in latest fallout from Epstein ties on.ft.com/3trHhmu - German prosecutors file first charges in Wirecard fraud on.ft.com/3fjG1JQ - France eases ban on travellers from the UK on.ft.com/3nlX0iP - ...

BRIEF-Biogen - To Continue To Urge CMS To Align Medicare Coverage For Class Of Amyloid-Directed Therapies With Populations Studied In Respective Clinical Trials, For Appropriate Use
https://www.reuters.com/article/brief-biogen-to-continue-to-urge-cms-to/brief-biogen-to-continue-to-urge-cms-to-align-medicare-coverage-for-class-of-amyloid-directed-therapies-with-populations-studied-in-respective-clinical-trials-for-appropriate-use-idUSFWN2TR1ET

Jan 12th, 2022 - Jan 12 (Reuters) - Biogen Inc: * BIOGEN - TO CONTINUE TO URGE CMS TO ALIGN MEDICARE COVERAGE FOR CLASS OF AMYLOID-DIRECTED THERAPIES WITH POPULATIONS STUDIED IN RESPECTIVE CLINICAL TRIALS, FOR APPROPRIATE USE * BIOGEN - COVERAGE WITH EVIDENCE DEVELOPMENT (CED) UNDER A RANDOMIZED CLINICAL TRIAL WILL EXCLUDE ALMOST ALL ALZHEIMER’S PATIENTS WHO MAY BENEFIT Source text for Eikon: Further company co...

EXCLUSIVE-Pfizer to cut U.S. sales staff as meetings move to virtual
https://www.reuters.com/article/pfizer-layoffs/exclusive-pfizer-to-cut-u-s-sales-staff-as-meetings-move-to-virtual-idUSL1N2TR2DR

Jan 11th, 2022 - Jan 11 (Reuters) - Pfizer Inc said on Tuesday it is reducing its U.S. sales staff as it expects doctors and other healthcare providers to want fewer face-to-face interactions with sales people after the COVID-19 pandemic ends. The move comes as the company is expected to announce more than $80 billion in revenue in 2021 on strong sales of the COVID-19 vaccine it developed with Germany’s BioNTec...

U.S. judge rejects Facebook request to dismiss FTC antitrust lawsuit
https://www.reuters.com/article/tech-antitrust-facebook/u-s-judge-rejects-facebook-request-to-dismiss-ftc-antitrust-lawsuit-idUSL1N2TR2E7

Jan 11th, 2022 - WASHINGTON, Jan 11 (Reuters) - The U.S. judge hearing the Federal Trade Commission’s antitrust case against Facebook said on Tuesday that he would not dismiss the government’s lawsuit.

BRIEF-Thermo Fisher Scientific Exec Says Pricing Is Going To Be Higher In 2022 Than In Past Years- JPM Conf
https://www.reuters.com/article/brief-thermo-fisher-scientific-exec-says/brief-thermo-fisher-scientific-exec-says-pricing-is-going-to-be-higher-in-2022-than-in-past-years-jpm-conf-idUSFWN2TR0TP

Jan 11th, 2022 - Jan 11 (Reuters) - Thermo Fisher Scientific Inc: * THERMO FISHER SCIENTIFIC EXEC SAYS DEMAND FOR VACCINES WILL BE RELEVANT AT LEAST INTO 2023, HARDER TO TELL BEYOND THAT- JPM CONF * THERMO FISHER SCIENTIFIC EXEC SAYS PRICING IS GOING TO BE HIGHER IN 2022 THAN IN PAST YEARS- JPM CONF Further company coverage:

BRIEF-Abbott Laboratories Exec Says Expect Covid-19 Testing Demand Strength To Continue In The More Immediate Future- JPM Conf
https://www.reuters.com/article/brief-abbott-laboratories-exec-says-expe/brief-abbott-laboratories-exec-says-expect-covid-19-testing-demand-strength-to-continue-in-the-more-immediate-future-jpm-conf-idUSFWN2TR0OZ

Jan 11th, 2022 - Jan 11 (Reuters) - Abbott Laboratories: * ABBOTT LABORATORIES EXEC SAYS SAW BIG SURGE IN THE UNITED STATES AND INTERNATIONALLY IN COVID-19 TEST DEMAND FOR DIAGNOSING AND SCREENING AROUND THANKSGIVING AND CHRISTMAS- JPM CONF * ABBOTT LABORATORIES EXEC SAYS COVID-19 TESTING WILL EVENTUALLY BE RAMPED DOWN BUT THERE WILL BE A PORTION THAT WILL BE SUSTAINED- JPM CONF * ABBOTT LABORATORIES EXEC SAYS ...